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The accumulation of adenosine is strongly correlated with the need for sleep and the
detection of sleep pressure is antagonised by caffeine. Caffeine also affects the circadian
timing system directly and independently of sleep physiology, but how caffeine mediates
these effects upon the circadian clock is unclear. Here we identify an adenosine-based
regulatory mechanism that allows sleep and circadian processes to interact for the optimi-
sation of sleep/wake timing in mice. Adenosine encodes sleep history and this signal
modulates circadian entrainment by light. Pharmacological and genetic approaches demon-
strate that adenosine acts upon the circadian clockwork via adenosine A1/A2A receptor
signalling through the activation of the Ca2+ -ERK-AP-1 and CREB/CRTC1-CRE pathways to
regulate the clock genes Per1 and Per2. We show that these signalling pathways converge
upon and inhibit the same pathways activated by light. Thus, circadian entrainment by light is
systematically modulated on a daily basis by sleep history. These findings contribute to our
understanding of how adenosine integrates signalling from both light and sleep to regulate
circadian timing in mice.
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In mammals, the suprachiasmatic nuclei (SCN) house the“master circadian pacemaker”. The SCN is comprised ofmultiple coupled neurones, each of which contain the mole-
cular machinery to generate a circadian oscillation. The molecular
clockwork in the SCN is aligned (entrained) to the astronomical
day by changes in the quantity and quality of light at dawn and
dusk, detected by specialised photoreceptors within the eye1.
Light leads to the upregulation of two critical clock genes, Per1
and Per2, whose expression sets the phase of entrainment of the
molecular clockwork2. The SCN, in-turn, coordinates the timing
of peripheral circadian clocks distributed throughout the organ
systems of the body. It is worth emphasising that peripheral
clocks can be entrained by multiple biological signals, including
temperature, metabolites and hormones such as glucocorticoids.
By contrast, the SCN is primarily entrained by light. For example,
the SCN is largely unresponsive to glucocorticoids3, although
there is evidence that non-photic stimuli including exercise also
contribute to SCN entrainment4–8. However, the SCN is sensitive
to caffeine9–11, suggesting that there exists an endogenous
adenosine-based regulatory pathway that is of profound impor-
tance to circadian timekeeping. However, until now, this pathway
has not been elucidated.
Caffeine is the world’s most widely consumed stimulant and
the most popular psychoactive drug12. Caffeine has multiple
biological targets, but its alerting effects that counter sleep
pressure13,14 are mediated by an antagonistic action on adenosine
receptors15. In addition to sleep, several recent studies have
shown that caffeine can also affect the circadian timing system
directly and independently of sleep physiology9,10,16,17. Caffeine
has been shown to: (i) alter clock gene expression of peripheral
clock cells in vitro; (ii) change the phase of locomotor rhythms in
mice; and (iii) alter the frequency of action potentials within the
SCN, both ex-vivo and in vivo9,10,16,17. In addition, caffeine
enhances phase-shifting responses to light in humans10 and also
potentiates the effect of light in multiple other species16–18.
How and why clock mechanisms should be sensitive to caffeine
has remained a mystery. Because of the importance of adenosine to
sleep/wake behaviour, and since sleep/wake timing and the circa-
dian system are so intimately connected19, we hypothesised that an
adenosine-based regulatory mechanism that is sensitive to caffeine
might allow sleep and circadian processes to interact in a dynamic
world for the optimisation of sleep/wake timing.
In this paper, we describe a signalling pathway downstream of
adenosine receptors that directly regulates entrainment and
identify adenosine A1/A2A receptor antagonists that specifically
target this pathway. Caffeine and adenosine altered clock gene
expression and circadian rhythms in vitro and in vivo via the
Ca2+-ERK-AP-1 pathway. We report that the significance of
adenosine signalling is to encode sleep/wake history to the clock
and modulate its response to light in mice. Furthermore, we show
that clinically safe adenosine receptor antagonists delivered to
mice at specific times act like light to phase-shift circadian
rhythms, and also enhance re-entrainment to shifted light dark
cycles. Therefore, we show that this signalling system provides a
robust therapeutic target for the stabilisation of circadian rhythm
disorders.
Results
Our data, along with published findings, show that caffeine
lengthens circadian period in cultured cells (Supplementary
Fig. 1a, b)9,10. We therefore predicted that adenosine will act as a
cell autonomous modulator of the circadian clockwork. Adeno-
sine receptors occur as the Gs (stimulatory) coupled A2A and A2B
subtypes and the Gi (inhibitory) coupled A1 and A3 subtypes20. In
U2OS cells, which express both A2B and A1 receptors
(Supplementary Fig. 1c), we observed that adenosine led to a
concentration-dependent period-lengthening (Supplementary
Fig. 2d, e). Further, knockdown of the A2B and A1 receptors had
opposing effects upon period length (Supplementary Fig. 1f–h),
consistent with their receptor pharmacology. We also decreased
adenosine by the addition of adenosine deaminase (ADA), which
degrades adenosine to inosine in the culture medium and
observed decreased period length (Supplementary Fig. 1i, j).
Collectively, these in vitro results demonstrate a constitutive role
for adenosine as a cell-autonomous regulator of circadian
rhythms.
To delineate the signalling pathways downstream of adenosine
receptors that couple to the circadian clock, we tested a panel of
different adenosine receptor antagonists and agonists. IB-MECA,
an adenosine receptor agonist, activated a classical cAMP-CREB
pathway that resulted in a rapid increase in PER1 and PER2
expression and increased period length (Fig. 1a–e). This pathway
is similarly activated in SCN neurones in response to light1.
However, and surprisingly, we found that several adenosine
antagonists also increased period length (Fig. 1f, g, Supplemen-
tary Fig. 2a–c). Importantly, these antagonists did not elevate
cAMP or CRE signalling (Fig. 1h–i, Supplementary Fig. 2d–g),
but they did induce the expression of PER1 and PER2, suggesting
the existence of an alternate pathway for adenosine-mediated
regulation of the molecular clockwork. Furthermore, those drugs
that targeted both A1 and A2A receptors (CGS15943, henceforth
referred to as CGS and JNJ40255392, henceforth referred to as
JNJ) were the most potent class of modulators (Fig. 1j, Supple-
mentary Fig. 2h–k). We suggest that this is due to hetero-
dimerisation of adenosine receptors, which has been shown
previously to differentially activate downstream signalling
cascades21. Finally, to rule out off-target effects, we showed that
the adenosine receptor antagonists failed to lengthen Per2-Luc
rhythms after knockdown of adenosine receptors (Supplementary
Fig. 2l–n).
In order to identify the CREB-independent transcriptional
pathway downstream of adenosine receptor antagonism, we
employed the unbiased transcription factor screening approach
BC-STARPROM22 that identifies DNA response elements (REs)
using a library of barcoded reporter luciferases. CGS increased
significantly the reporter luciferase signal from 8 clones within
the STARPROM library (Fig. 2a). Bioinformatic analysis showed
that 7 of the 8 clones contained a FOS/JUN (AP-1)-like RE,
TGATTCA (AP-1 RE= TGACTCA) (Fig. 2b and Supplementary
Fig. 3a). In order to experimentally identify the factors that bound
to the putative RE and flanking elements in an unbiased assay, we
used a biotin-tagged oligonucleotide (from clone 3) to immuno-
precipitate DNA binding proteins from the nuclear fraction of
U2OS cells treated with CGS for 4 h. Approximately 40 proteins
were enriched by CGS (Supplementary Dataset 4). An siRNA-
mediated knockdown screen of the most enriched proteins
showed that FOS and JUN (AP-1) silencing decreased the
expression of clone3 under baseline conditions and decreased its
response to CGS (Fig. 2c and Supplementary Fig. 3b, c). Impor-
tantly, we saw attenuated period lengthening by CGS in Per2-Luc
U2OS cells after knockdown of either or both FOS and JUN
(Fig. 2d, e). Analysis of the human PER2 gene indicated several
putative AP-1 REs, including some that were highly conserved
and previously validated by ChIP-Seq as reported on ENCODE23
(Fig. 2d). By contrast, although there are putative AP-1 REs in the
PER1 promoter, they are not well conserved, suggesting that the
AP-1 pathway is less important in the regulation of PER1. Sup-
porting this hypothesis, adenosine receptor antagonists show
greater PER2 induction compared to PER1 (Fig. 1j).
To define the signalling elements between adenosine receptors
and AP-1, we silenced a series of members of the MAPK-ERK
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signalling pathway that have been shown to activate AP-124 in
U2OS cells, and then tested the efficacy of CGS at lengthening
period using a concentration response curve (Fig. 2f). We then
calculated EC50 of CGS at period lengthening under each
knockdown condition from the curves (Fig. 2g) and found that
silencing ERK1 abolished the period-lengthening effect of CGS.
By contrast, silencing the Jun Kinases (JNKs) had no effect upon
the action of CGS (Supplementary Fig. 3b, c). Further, CGS-
induced ERK phosphorylation (Fig. 2f) led to increased AP-1
activity and cJUN transcription (Fig. 2g). Finally, we identified
Ca2+ as the messenger activating ERK1 following CGS applica-
tion (Fig. 2h). This is consistent with previous reports showing
that all four adenosine receptors can modulate Ca2+ release20,21.
Increased cytosolic Ca2+ can lead to the activation of ERK1/2 via
multiple pathways including RAS, the protein tyrosine kinase
PYK2 and Calmodulin Kinase 125. In short, these results define a
Ca2+-ERK1/2-AP-1 pathway downstream of adenosine receptor
antagonism in U2OS cells. These findings are outlined in Sup-
plementary Fig. 6.
To place our in vitro findings into a physiological and beha-
vioural context, we explored the role of adenosine signalling upon
circadian rhythms within the SCN. We found that the SCN
expresses both A1 and A2A adenosine receptors in a circadian
manner (Fig. 3a, b). Both CGS and JNJ lengthened period in
ex vivo cultured Per2::Luc SCN slices (Fig. 3c) and adenosine
itself reduced period presumably due to the prevalence of Gi
coupled A1 receptors. Also, CGS and JNJ increased ERK and
CREB phosphorylation (Fig. 3d) and induced Per1/2 (Fig. 3e). We
speculate that this is likely due to the different receptor dis-
tribution within the SCN, with inhibitory A1 receptors pre-
dominating. Here, the dominant effect of the antagonist would be
inhibition of the Gi-PKA system, which would lead to an increase
in cAMP and thus CREB phosphorylation. In contrast, the A2B
receptors present in U2OS cells are Gs and Gq coupled, therefore
their antagonism would not lead to CREB phosphorylation.
However, adenosine receptor signalling is known to be very
complex, with adenosine receptors forming heterodimers, mod-
ulating the release of other signalling messengers and neuro-
transmitters, and thus engaging different pathways depending on
receptor distribution26. Therefore, what is provided above is a
proposed mechanism based on the available data.
The signalling pathways we describe for adenosine have strong
parallels with those activated by light27. For example, Fos is a
classical light-activated gene28,29 and AP-1 binding to DNA
increases after a light-pulse within the SCN27. However, although
AP-1 activation is correlated with light exposure, its role in
mediating the transcriptional response of the clock to light has
remained unresolved. Indeed, CREB transcription alone has been
considered as the primary mediator of light responses. However,
unphosphorylated CREB can bind to and repress AP-1 REs30,31.
As a result, the robust phosphorylation of CREB and the
expression of FOS would act synergistically to amplify down-
stream AP-1 transcription. Our data would support this conclu-
sion. A motif analysis of the genes that comprise the SCN light-
regulated transcriptome2 showed enrichment of both CRE and
AP-1 REs (Fig. 2b), underscoring the importance of AP-1 in
augmenting the transcriptional responses to light. These findings
are also précised in Supplementary Fig. 6.
As adenosine receptor antagonists activate the signalling
pathways downstream from light within the SCN, we hypothe-
sised that these antagonists will induce phase-shifts of the circa-
dian clock following administration at specific times during the
night. In addition, several non-photic cues, including cAMP itself
induce phase advances of the clock in vitro and in vivo during the
































































































































































Fig. 1 Mechanisms of action of adenosine signalling to the clock. a 10 μM IB-MECA increased period length in Bmal1-Luc U2OS cells which revert to
normal rhythms after washout (arrow) in a concentration-dependent manner (traces are an average of n= 4) as shown in b (n= 4, DMSO control samples
in red); c IB-MECA increases cAMP levels (as monitored by the cAMP-GLO assay) in a concentration-dependent manner (n= 6); d 30 µM IB-MECA
increases phosphorylation of CREB (pCREB S133) as shown by Western blot (n= 3), Forskolin positive control; e PER1 and PER2 mRNA levels in U2OS
cells increase after administration of 10 µM IB-MECA (n= 4, p < 0.001 with two-way ANOVA, p= 0.000074 at 2 h for PER1, and p=
0.00000000000021 and 0.000000024 at 2 h and 4 h for PER2, Šídák’s multiple comparisons test). DMSO control in black. f 10 μM CGS15943 (CGS)
increased period length in Bmal1-Luc U2OS cells, which revert to normal rhythms after washout (arrow), in a concentration-dependent manner as shown in
g, n= 4 DMSO control samples in red. h cAMP increases as monitored by the cAMP-GLO assay, CGS (30 µM) administered at arrow, controls DMSO, 10
µM Forskolin and IB-MECA 1 µM shown, n= 3; i 30 µM CGS did not increase phosphorylation of CREB as shown by Western blot (n= 3). DMSO control
shown; note d and i are part of the same blot, forskolin positive control. j PER1 and PER2 mRNA levels in U2OS increase after treatment with 10 µM CGS
(n= 4, p= 0.03 for PER1 and p= 0.0006 for PER2 with two-way ANOVA). DMSO control in black.
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day32–34 and a few enhance re-entrainment to a shifted light dark
cycle35–37. Therefore, we tested the effects of JNJ at times that
cause maximum delay in response to light (CT16), but also when
non-photic cues would elicit a large advance (ZT6), and in a re-
entrainment paradigm. Because JNJ has better compound solu-
bility and a more detailed pharmacokinetic characterisation38,
our in vivo experiments were largely undertaken with this drug,
although findings were confirmed with at least one other A2A/A1
antagonist. JNJ administered intraperitoneally (i.p.) 6 h after light
onset (zeitgeber time 6; ZT6) elicited large phase advances in
circadian wheel-running behaviour (Fig. 4a–c). Since adenosine-
mediated regulation of the clock shares parallels with light, we
also investigated the effect of JNJ administration 4 h after activity
onset (the time of maximum light-induced phase delays in mice)
and found that JNJ similarly elicited phase delays (Fig. 4d–f).
Further, we explored whether JNJ and other A2A/A1antagonists
could enhance re-entrainment to a shifted light-dark cycle, and
observed this to be the case (Fig. 4g–i). In agreement with our
in vitro findings, drugs that targeted both the A2A and A1
receptors were the most effective at phase-shifting and enhancing
re-entrainment (Fig. 4j, k). We then studied the properties of
Istradefylline (KW6002), which is an A2A antagonist already in
clinical use for the treatment of Parkinson’s disease.
KW6002 significantly phase shifted circadian rhythms in wheel-
running behaviour (Supplementary Fig. 4c–h, Fig. 4j). Collec-
tively, our data show that adenosine receptor antagonists have a
significant and direct effect upon circadian behavioural rhythms.
Having established how adenosine regulates circadian rhythms,
we next addressed the biological relevance of this phenomenon.
Extracellular adenosine levels track metabolic activity and are
thus key indicators of metabolic state. Within the brain, the build-
up of adenosine, presumed to be from glial and astrocyte sources,
provides a strong correlate of the sleep homoeostatic drive13,39,
and these changes are monitored by different parts of the brain40,
most notably by the basal forebrain41, but also within the
hippocampus42 and hypothalamic nuclei such as the ventrolateral
preoptic nuclei (VLPO), or “sleep switch”40. Significantly, infu-
sion of A2A agonists within the basal forebrain43 or the
hypothalamus44 will induce sleep. Here we show that adenosine
within the SCN shows day–night differences, and is lower at
the end of the sleep phase (Fig. 5a) when compared to the
beginning of sleep. As a result, adenosine could encode infor-
mation on sleep/wake history to the molecular clockwork. Indeed,
there is evidence for such an interaction. For example, increasing
the homoeostatic drive for sleep through sleep deprivation
changes patterns of peripheral clock gene expression in both
mice and humans45,46. Whilst such links have been reported, the
mechanisms that drive these interactions have remained obscure.
We studied the effects of adenosine on circadian behaviour
in vivo, by utilising the Adk-Tg transgenic mouse which over-
expresses human adenosine kinase (ADK)47. ADK phosphor-
ylates free adenosine into adenosine monophosphate (AMP), thus
overexpression of ADK enhances the metabolic clearance of
adenosine. The Adk-Tg mouse shows reduced slow wave power
in all vigilance states as defined by electroencephalography (EEG),
and significantly, a reduced build-up of slow-wave activity after
sleep deprivation48. This is consistent with reduced adenosinergic
tone, which we confirm in the SCN and basal forebrain (Fig. 5 a).
In the mouse SCN, we predicted that reduced adenosine would
lead to less inhibition through the adenosine A1 Gi-coupled
a
DMSO CGS
0.5h - 8h 0.5h - 8h
b
Human     tgaatcagcttt
Mouse     tgaatcagcttt
Dog      tgaatcagcttt


















































































































Fig. 2 STAR_PROM identifies ERK-AP1 pathway downstream of adenosine signalling. a Time course of RNA-seq reads for barcoded luciferase from BC-
STARPROM reporter transfected U2OS cells treated with DMSO control or 30 μM CGS (n= 2, timeline – 0, 0.5, 1, 2, 4 and 8 h after treatment). The enlarged
cluster shows the top 20 upregulated clones, of which 8 were statistically significant (boxed, p < 0.05, two-way ANOVA). b Consensus sequence from the
upregulated clones with the consensus AP-1 RE and the light-regulated SCN transcriptome motif shown for comparison. The conservation of the AP-1 RE in the
PER2 gene is indicated, genomic position 2:238287740 (hg38) in humans and 1:91458384 (mm9) in mice. c Reporter activity of clone3 after knockdown of FOS
and JUN (siAP1 – grey) when compared with a non-targeting siRNA control (siNT – blue) in response to CGS (30 μM – C30, 3 μM – C3 or DMSO, n= 4, single
trace shown for clarity). d, e Concentration response curves and EC50 of CGS-mediated period lengthening in Per2-Luc U2OS cells after knockdown of the genes
indicated (n= 4, DMSO controls outlined in red *= p < 0.05, ***= p < 0.001 One-way ANOVA, Bonferroni post-hoc test); EC50 error calculated from raw data
in (n). f Increased phosphorylation of ERK1/2 (pT202/Y204 – pERK) with 30 μMCGS treatment in U2OS cells (48%± 18% increase, p=0.03, n= 3 to 6, one-
way ANOVA, Tukey’s post-hoc test). g cJUN mRNA increases after treatment with 30 μM CGS – C30 (n= 4, **= p < 0.0021 at 2 h, Šídák’s multiple
comparisons test). h Ca2+ release in response to 10 µM CGS administered at arrow, measured by Fura2 reporter. IB-MECA caused no change. Dashed lines
indicate range of data. Individual data points overlaid on all charts with line representing mean, unless otherwise indicated, error bars= S.E.M.
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receptor, and therefore increased period length in constant dark
and larger phase shifts in response to light. Both results were
observed. Greater differences in phase shifting were seen at CT22
vs CT14 (p < 0.05 for time with a two-way ANOVA), reflecting
the naturally lower adenosinergic tone at CT14 following sleep
(Fig. 5b–d). These results suggest that the biological relevance of
adenosine signalling to circadian rhythms is to incorporate sleep
history into the clockwork. It has been shown previously that
sleep deprivation attenuates phase shifts to light, and also that A1
receptors attenuate light signalling16,49–53. Indeed, we confirm
that sleep deprivation between CT8-14 reduces the size of phase
shifting responses to a light pulse at CT14, seen but this effect is
reversed when the animals are pre-treated with JNJ (Fig. 5e). To
confirm that this is as a result of adenosine acting upon clock
gene expression, we measured Per1/2 expression within the SCN
after sleep deprivation. We found that sleep deprivation during
the second half of the light phase (ZT6-12, Fig. 5f, g) decreased
Per1/2 expression within the SCN, consistent with increased
adenosine-A1 signalling. Confirmation that the mice were
indeed sleep deprived comes from our demonstration that
Homer1a and Egr1 (both markers of sleep deprivation) were
upregulated (Supplementary Fig. 5a–c45). Our findings are con-
sistent with a previous study showing that there is decreased Per2
expression within the SCN following induced activity during the
sleep phase54, but differ from another report suggesting that there
are no changes in Per2 within the SCN after sleep deprivation55.
We suggest that this discrepancy arises from the different
methodological approaches used; both the first study and ours
allowed access to a running wheel and were conducted at the
same time (ZT6-12); however, the latter55 was conducted without
a running wheel, ZT0-6. Significantly, in our studies, the decrease
in Per2 in the SCN was abolished by administration of JNJ
(Fig. 5h), strengthening our proposal that adenosine signals
sleep–wake history to the circadian pacemaker.
Collectively, our findings suggest that light signalling to the
molecular clockwork can be altered by modulating adenosine
signalling. Thus, the inhibition of adenosine-A1 signalling
through A1 antagonists will enhance the phase-shifting effects of
light, whereas A1 agonists will diminish the impact of light. We
predicted that the converse would be true of A2A signalling, and
this was confirmed. Administration of specific A1 and A2A ago-
nists and antagonists (Fig. 5i–m) altered the size of both the phase
delay and advance portions of the phase response curve (PRC) to
light (see below for further discussion). Thus, our results
demonstrate that sleep history influences circadian entrainment







































































































































Fig. 3 The SCN expresses adenosine receptors and responds to adenosine receptor antagonists. a Expression of adenosine receptor (Adora) subtypes
within the mouse SCN at two different circadian times (n= 5, A1 at a higher concentration compared to A2A p= 0.0138, and at higher levels at CT5 (0.178
± 0.04) compared to CT17 (0.073 ± 0.03) p= 0.0223, two-way ANOVA with Bonferroni post-hoc test). b Immunohistochemistry for A2A and A1 receptor
subtypes showing expression within the SCN (inset). c SCN slice cultures from Per2::Lucmice treated with the A2A/A1 antagonists CGS15943 (CGS) 10 μM
(red, period length 25.1 ± 0.1 h, n= 3) and JNJ40255392 (JNJ) 10 μM (blue, period length 26.24 ± 0.3 h; n= 5; DMSO 23.1 h ± 0.3 h n= 5; p=
0.0000076439 for CGS and 0.0484 for JNJ, Tukey’s multiple comparisons test. d Western blot with antibodies against pERK1/2 (pT202/Y204 - pERK)
and pCREB (pS133) within the SCN collected from mice 45min after i.p. injection of CGS or JNJ at 5 mg/kg at CT6, SCN collected from mice exposed to a
30min CT16 light pulse included for comparison (n= 7 from two experiments of n= 3 and n= 4, uncut blots shown in Supplementary material, one-way
ANOVA with Bonferroni post-hoc test). Box plots show relative expression. e Increases in Fos, Per1, and Per2mRNA within the SCN after i.p. injection of JNJ
at CT6 after 1, 4 and 6 h respectively, n= 6–10. p= 0.0387 for Fos, 1 h; p= 0.0183 for Per1, 4 h and p= 0.0322 for Per2, 6 h, one-way ANOVA with
Bonferroni post-hoc test. Tukey’s box plots used throughout (central line – mean, box represents 25th to 75th percentile data, whiskers are 1.5
interquartile range).
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Discussion
The integration of sleep/wake behaviour and circadian rhythms,
via the mechanisms we outline in Supplementary Fig. 6, also
provides greater clarity on the mechanisms that mediate circadian
entrainment to light. Whilst previous studies have highlighted the
importance of CREB-mediated transcription for circadian phase
shifts to light56, this is not the only pathway. It is important to
stress that CREB targets represent only 20% of the light-regulated
SCN transcriptome2 and mice expressing a dominant negative
CREB (CREB S133A) show only attenuated circadian responses
to light57. The work presented here shows that AP-1 provides an
additional regulatory target for both light and adenosine. AP-1
binding to DNA and Fos induction has long been used as a robust
marker of SCN activation27–29, and Fos knockout mice show
attenuated responses to light58, but the signalling function of FOS
has remained poorly defined. The clear relationship between FOS
activation and Per transcription is discussed in the results and
illustrated in Supplementary Fig. 6. However, we speculate that
this is unlikely to be the only role for FOS. For example, FOS has
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Fig. 4 A2A/A1 adenosine receptor antagonists modify circadian behaviour. a–c Mice were housed in 12:12 L:D cycle, (grey – dark, white – light, black
vertical bars show wheel running activity). At the red arrow (ZT6), animals received an i.p. injection of a vehicle or b 5mg/kg JNJ40255392 (JNJ) and
released into constant dark (DD). Activity onset on subsequent days is indicated by red line and c phase shifts expressed as a Tukey’s box plot (n= 12 and
8, **= p= 0.0012, one-way ANOVA with Dunnett’s multiple comparisons test). d Mice were housed in DD (CT16) received either vehicle or e 5mg/kg
JNJ at red arrow (CT16) and f phase shifts measured (n= 11 and 10, *p= 0.007, t-test). g–iMice were housed in 12:12 LD received either g vehicle (n= 12)
or h JNJ at 5 (n= 12), 1 (n= 6) or 0.2 (n= 6) mg/kg at ZT6 (red arrow) and LD cycle advanced by 6 h. The phase of activity was measured the day
after the injection (red line) (i) (n as above). JNJ in a dose-dependent manner enhances re-entrainment (p= 0.0031, one-way ANOVA). j JNJ at 5 mg/kg
(n= 8) causes the largest phase shifts when administered at CT6 (p= 0.0012) compared with either caffeine (n= 9, 50mg/kg, p= 0.0063) or KW6002
(n= 5, 1 mg/kg, p= 0.0151) (one-way ANOVA with Dunnett’s multiple comparisons test, no significant difference between caffeine and JNJ treatment).
k JNJ is more effective than the control and the specific A2A antagonist KW6002 1 mg/kg, and the specific A1 antagonist KW3902 1 mg/kg for re-
entrainment as measured using the 6 h phase advance protocol, n= 12. One-way ANOVA, Dunnett’s multiple test correction, p= 0.0023 for JNJ and
p= 0.0342 for KW6002 vs vehicle. Tukey’s box plots used throughout (central line – mean, box represents 25th to 75th percentile data, whiskers are 1.5
interquartile range).
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Fig. 5 Altered levels of endogenous adenosine regulate circadian rhythms in vivo. a Basal forebrain (BF) and SCN were collected from wild type and
human adenosine kinase overexpressing transgenic mice (Adk-Tg - ADK) at indicated circadian times. Each sample is a pool of 5–7 individual tissue
punches. b Phase shifting in Adk-Tg animals (ADK-Tg) and wild type (WT) in response to a 1 h 200 lux light pulse at CT14 (n= 10 and 9, no significant
difference, t-test) (b) and CT22 (c) (n= 14 and 8, p= 0.0439, t-test). d Free running period of the same mice in DD (n= 12 and 9, p= 0.0071).
*= p < 0.05, **= p < 0.01 t-test. e Behavioural phase-shifts in response to a 30min 20 lux light pulse (LP) at CT14 (n= 14) is attenuated by sleep
deprivation (SD, n= 10) for the previous 6 h (p= 0.0001, n= 9–11), but potentiated when pretreated with 5mg/kg JNJ (n= 9, p= 0.0007) one-way
ANOVA with Tukey multiple comparisons. f Sleep deprivation (ZT6-12) reduces the expression of Per1 (n= 11,11, t-test, p= 0.031) and g Per2 mRNA (n=
12,12 t-test, p= 0.025) within the SCN. h JNJ (5mg/kg i.p. administered at ZT6) reverses the attenuation of Per2 within the SCN (n= 9,11, 8, p= 0.0006,
one-way ANOVA with Dunnett’s multiple test correction). i–m Behavioural phase shifts in response to light and drugs that modulate adenosine signalling
via specific A1 or A2A receptor agonists or antagonists: i N6CPA (A1 agonist, 0.5 mg/kg, p= 0.0164) and CGS21680 (A2A agonist, 0.5 mg/kg, p= 0.0046)
(n= 12, 9, 13) and j KW3902 (A1 antagonist, 1 mg/kg, p= 0.0051) and KW6002 (A2A antagonist, 1 mg/kg) (n= 11, 9, 11). In i and j the phase-delaying
phase shifts induced by a light pulse (30min, 10 lux) delivered at CT16 are shown. For comparison, the phase-advance induced by a 30min 100 lux light
pulse at CT22 is shown in k (n= 10, 9, 10) and l (n= 10, 8, 8) (p= 0.0188 for KW3902 and p= 0.0078 for KW6002. One-way ANOVA for i–l, Dunnett’s
multiple test correction. Tukey’s box plots used throughout (central line – mean box represents 25th to 75th percentile data, whiskers are 1.5 interquartile
range). m Representative actograms are shown for i–I.
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opening in response to neuronal activity within the dentate
gyrus59. It is possible, therefore, that FOS may also induce similar
changes in chromatin within SCN neurons. By changing chro-
matin accessibility to transcription factors, entrainment will be
subject to additional regulatory controls. As illustrated in Sup-
plementary Fig. 6, our results suggest that whilst CREB/CRTC1-
CRE transcription drives a rapid increase in Per1 transcription,
AP-1 activation via FOS/JUN mediates a slower transcriptional
drive upon Per2. Such a differential activation of Per1/Per2
expression would explain why Per1 rises rapidly within the SCN
after a light pulse, whilst Per2 shows a slower rise and decline in
expression levels60. The functional significance of this differential
activation remains to be fully resolved, but presumably relates to
an increased level of precision and signal strength for circadian
entrainment via these pathways.
Under conditions of sleep deprivation, corresponding to a high
adenosinergic tone, adenosine attenuates light-induced phase
shifts. This observation is interesting in the context of entrain-
ment. In all species studied, there is a phase response curve (PRC)
to light such that light delays the circadian clock at dusk and
advances the clock at dawn61,62. In this manner, light exposure at
dawn and dusk ensures that circadian rhythms are appropriately
aligned/entrained to the solar day on a daily basis. Mice have
circadian rhythms that are significantly shorter than 24 h, and so
will show a daily phase advance in behavioural rhythms. As a
result, mice require a daily phase delay to ensure that the clock is
entrained to the 24 h day. Without such delaying cues, the
endogenous delaying sleep/wake cycle of mice will drift earlier in
time. Significantly, mice would have high levels of adenosine
at dawn (following a night of activity), whilst adenosine levels
will be low at dusk (following a day of sleep). Because
adenosine acts to inhibit the effects of light on the circadian clock,
dusk light will induce large phase delays, whilst dawn light will
induce small phase advances. Whilst these observations may not
hold true in all species, suggesting there are more factors at play
here than just adenosine, we speculate that the reverse would be
true in humans, as we sleep during the night and have longer
clocks (>24 h). In this manner, light and sleep/wake history could




Animals. C57Bl/6 mice, Period2::Luciferase transgenic mice1 and AdK-Tg2 were
used. All studies were conducted on animals over 50 days of age, male only in the
case of behavioural studies, females also included for ex vivo work. Unless other-
wise indicated, animals were group housed with food and water ad libitum under a
12:12 h LD cycle. All procedures were performed in accordance with the UK Home
Office Animals (Scientific Procedures) Act 1986 and the University of Oxford’s
Policy on the Use of Animals in Scientific Research (PPL 70/6382, PPL 8092CED3),
as approved by the local Animal Care and Ethical Review committee (ACER).
Animals were sacrificed via Schedule 1 methods in accordance with the UK Home
Office Animals (Scientific Procedures) Act 1986.
Cell lines. Cells from the U2OS (HTB-96) line were obtained, tested and identified.
The cells were cultured in T-75 flasks, in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% foetal bovine serum (FBS) and 1% penicillin-
streptomycin (P/S) at 37 °C in a humidified atmosphere at 5% CO2. The cells were
sub cultured every 2 to 4 days in a 1:2 to 1:6 ratio, in accordance with the ATCC
recommendations. The cells were counted using a haemocytometer, and their
viability in a culture was maintained at above 95%, measured with a Presto Blue
exclusion assay according to the manufacturer’s specifications.
Two clock reporter lines were used:
1. Per2-Luc U2OS: Bioluminescence recording in phenol-red free DMEM
supplemented with B-27 and 100⎧M luciferin potassium salt. Cells
synchronised with 100 nM dexamethasone.
2. Bmal1-Luc MMHD3: Cultured as reported in ref. 3. Briefly, cultured in
RPMI medium supplemented with 10% FBS, 1 × PSG, 10 µg/ml insulin, 55
ng/ml epidermal growth factor (EGF) and 16 ng/ml insulin like growth
factor-II (IGF-II). Cells synchronised with 200 nM dexamethasone followed
by bioluminescence recording in 25 mM HEPES-buffered serum-free
explant medium (pH 7.4) containing B-27 and 1 mM luciferin.
Method details
Animal drug administration. The drugs were formulated in a vehicle consisting of
5% Koliphor-HS15 (Sigma-Aldrich, UK) 5% Cyclodextran (Sigma-Aldrich, UK) in
0.9% saline. This vehicle was warmed to 37 °C and the indicated drugs kept at a
100x stock in DMSO and mixed at the appropriate concentration to be adminis-
tered at approximately 10 ml/kg intraperitoneal injection (n= 6 to 15, indicated
in each figure legend). Where the time point of injection was in the dark, the
procedure was conducted under dim red light.
Behavioural assays
Phase shifting. C57Bl/6 male mice (80 days or older) were maintained on running
wheels in light tight chambers on a 12:12 LD cycle on stable entrainment, were
released in complete darkness. At set times as indicated in the experiments, the
animals received an intraperitoneal injection (10 ml/kg) of drug constituted in
sterile saline with 5% Cyclodextrin (Sigma-Aldrich) and 5% Koliphor (Sigma-
Aldrich) and then allowed to free run in DD, running wheel activity data were
collected and analysed on Clocklab (Version 5, Actimetrics, Wilmette, IL).
Re-entrainment. C57Bl/6 male mice (80 days or older) were maintained on running
wheels in light tight chambers on a 12:12 LD cycle (100 lux from white LED lamps)
and injected with drugs as above at ZT6. The LD cycle was immediately advanced
by 6 h. Some adenosine receptor antagonists induce activity, which itself can shift
the clock. Therefore, running wheels were locked for 12 h immediately following
drug administration. Onset of activity on each day was used to measure phase
relative to the LD cycle, data analysed on Clocklab.
Sleep deprivation studies. C57Bl/6 male mice at 80–120 days of age were group
housed under a 12:12 LD cycle for 2 weeks with food and water ad libitum for
tissue collection, or singly housed in constant dark with access to running wheel for
behavioural studies. The sleep deprivation protocol consisted of novel object
introduction and manual gentle handling between ZT6-12 or as listed in appro-
priate figure legend. If tissues were required, at the end of the protocol animals
were sacrificed and tissues collected, otherwise animals were returned to the light
tight chambers and activity recorded continued. Where indicated in the experi-
ment, drugs were administered at the start of the sleep deprivation procedure
as above.
ADK-Tg studies. 14 ADK-Tg male mice (previously described in2,4 at 50–80 days
and 10 age-matched C57Bl/6 control male animals were housed in cages with
passive infrared sensors under a LD12:12 (light levels, light source). Phase shift
assays were carried out at CT14 and CT22 (1 h light pulse, light levels) after a single
day in DD and onset of activity on the subsequent 7 days was used to determine
phase. Data were analysed on Clocklab as above.
Tissue collection
SCN tissue collection. Animals were housed under a 12:12 LD cycle for 2 weeks with
food and water ad libitum. Animals then received either a drug injection with
alteration in the light dark cycle as described in the experiment and at set points
following drug administration were sacrificed by cervical dislocation. Sham-treated
mice not given a light pulse were dissected at each time point. Brains were removed
and placed into a brain matrix (Kent Scientific, Torrington CT, USA). Per2-Luc
transgenic animals1 were obtained from Prof. Joseph Takahashi, Northwestern
University.
For punches for mRNA/protein analysis. A skin graft blade (Swann-Morton,
Sheffield, UK) was positioned at Bregma −0.10 mm. A second blade was placed 1
mm caudal from the first, and a 1 mm thick brain slice was dissected. SCN punches
were taken using a sample corer (1 mm internal diameter, Fine Science Tools
GmbH, Heidelberg, Germany) from the brain slice (n= 4), flash frozen on dry ice
and stored at −80 °C prior to RNA extraction.
For SCN slice culture. Following euthanasia with isoflurane followed by cervical
dislocation, the animal was enucleated and the brain was removed using standard
methods. The brain was further blocked by removing the cerebellum and frontal
cortex whilst preserving the integrity of the SCN and further sliced to 250 μm
sections in NMDG aCSF using a compressatome (ref below). (93 mM NMDG,
2.5 mM KCl, 1.2 mM NaH2PO4, 30 mM NaHCO3, 20 mM HEPES, 25 mM glucose,
2 mM thiourea, 5 mM Na-ascorbate, 3 mM Na-pyruvate, 0.5 mM CaCl2 and
10 mM MgSO4). The slices were further micro dissected under a microscope and
transferred to membrane (Millicell Cell Culture Insert, 30 mm, hydrophilic PTFE,
0.4 µm, Millipore) in recovery media consisting Hanks Balanced Salt Solution
containing 100 nM MK801, 2.5 mM AP-V and 3 mM Glutathione reduced ethyl
ester for 1 h at 37 degrees and then cultured in 500 µL DMEM containing B27 in a
5% CO2 incubator.
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In vitro/ex vivo experiments
RNA extraction. Total RNA was extracted using the microRNeasy column method
(Qiagen, Hilden, Germany). Quality and quantity of RNA were measured using an
Agilent Bioanalyzer and a Nanodrop1000 (Thermo Fisher Scientific, Waltham, MA
USA), respectively.
Quantitative PCR (qPCR). RNA samples were prepared as described for microarray
hybridisation. cDNA was synthesised with a qScript cDNA synthesis kit (Quanta
Biosciences, Gaithersburg, MD), and quantitative PCR (qPCR) was conducted with
Sybr green. Relative quantification of transcript levels was done as described
previously5. The geometric mean of a minimum of three housekeeping genes was
used for normalisation (Gapdh, ActB, GusB and Rps9 for example).
Primer sequences in Supplementary dataset 1 and from ref. 6
RNAi. siRNA sequences in Supplementary dataset 2 were transfected with Lipo-
fectamine 3000 when in combination with plasmid or Lipofectamine RNAiMax
when alone (manufacturer’s instructions followed in both cases).
Luciferase cell-based circadian assays. For siRNA- and drug-based experiments,
cells were seeded at 5000 per well in native medium into white 384 well plates and
transfected with 50 nM siRNA the next day. Two days later, the cells were syn-
chronised with 100 nM dexamethasone and the medium was replaced with
requisite drugs formulated in DMSO as a 1000x stock (drug sources in Supple-
mentary dataset 3), and then sealed. Per2-Luc rhythms were recorded from a BMG
Labtech Fluostar Omega plate reader maintained at 36 °C and readings taken from
each well every hour (software – Omega Version 5.10 R2). Data were then analysed
using Multicycle rhythm analysis software (Actimetrics – Version 1.505).
STAR-PROM assay. This was conducted as previously reported in ref. 7. Briefly,
U2OS cells were cultured in 6-well plates and transfected with 1 ug of the STAR-
PROM plasmid library with X-TremeGENE (Roche). After 24 h, cells were serum
starved for 16 h and 30 μM CGS15943 or DMSO was added to the cells and RNA
was extracted at set time points, the luciferase transcript labelled and barcoded for
Illumina libraries preparation exactly as described in Gosselin et al.22. Library
quality and size were confirmed with a bioanalyser (Agilent) and spiked with 10%
of φX 174 (φX) bacteriophage DNA library to balance for AT/GC content.
Libraries were loaded on a rapid-mode flow cell and sequenced inside a HiSeq 2500
machine (Illumina), which produced ∼100M single reads of 100 nt each per
experiment. Bioinformatic analysis of reads was conducted as described in
Gosselin et al. briefly FastQ files were uploaded onto Galaxy (https://use.galaxy.org)
where 3′ end of the barcode was isolated from the luciferase sequence and
demultiplexed according to the index used to label each sample. The reads were
trimmed to isolate the bar code region and then counted in each sample. The
counts were then normalised and fold changes calculated in R (https://github.com/
randogp/STARprom).
Mass spectrometry assay on STAR-PROM clone. The clone3 sequence was syn-
thesised as both forward and reverse complement strands by Sigma Aldrich, UK.
The forward strand was tagged with biotin at the 3′ end and strands were annealed
using New England Biolabs buffer 3. 5 million U2OS cells were treated with
CGS15943 30 μM or DMSO control for 4 h followed by nuclear protein extraction
using NuN buffer8. The nuclear extract was incubated with the biotin tagged
strands and then the complexes were pulled down with Dynabeads M-280 Strep-
davidin tagged magnetic beads (Invitrogen). For these steps, the protocol published
by ref. 9 was followed. The pulled down proteins were then fragmented by filter
assisted trypsin digestion and analysed with LC-MS/MS mass spectrometry (Q
Exactive™ Hybrid Quadrupole-Orbitrap™ Mass Spectrometer). The resulting reads
were sorted by degree of enrichment in the CGS-treated samples and top 40
transcription factors chosen for further analysis (Supplementary dataset 4). The-
se were then further characterised by their expression levels in both U2OS cells
and the SCN (data from NCBI GEO / BioGPS.org) and the presence of a putative
binding element in the PER2 promoter (analysed on JASPAR). The resulting top 20
were then further analysed with knockdown and reporter assays as detailed below.
CRE-Luc and STAR-PROM reporter assays. Clone 3 was reconstructed by ligating 6
tandem copies of the sequence GCCAACGTAATCACCCAGTGATTCATC-
TAATTTCGCGAAGCGATTTTTTGTGTTTGACCTAGCATTGGCCGG-
GAAGCTGCAG flanked by the sequences GAAGGCTAGCAG and
GAAGCTTAG to enable insertion between the NheI and HindIII sites of the
pGL4.24 plasmid (synthesised by GeneArt, Invitrogen).
CRE-Luc (pGL4.29[luc2P/CRE/Hygro] Vector, encoding Luc2P luciferase
under the control of a strong cAMP response element (CRE) promoter containing
3 CRE elements within its sequence; Promega).
These constructs were transfected at 100 ng/well of a 384 well plate into U2OS
cells (4000 cells per well) cultured as above with Lipofectamine 3000 following
manufacturer’s instructions, either on its own or in combination with 50 nM
siRNA. After 24 h, the cells were maintained in serum-free DMEM containing 1
mM luciferin for 12–16h after which the drugs were added as described under
libraries and screening methods. Luminescence values were measured realtime in
FLUOstar OPTIMA or OMEGA Microplate readers. For comparative experiments,
drug concentrations of 10 μM were used as they were found to be optimal for
keeping cell toxicity below 5%, measured with the Presto Blue exclusion assay. In
the case of CRE-Luc, forskolin was used as a positive control, and 1% DMSO was
used as a negative control.
cAMP GloSensor assay. The GloSensor™ cAMP Assay (Promega) was used for
detecting changes in the intracellular levels of cAMP. Initially, a Greiner Bio-One
96 Well Plate (white, TC treated) was seeded at 8000 cells per 100 μl well, as
described above. After 24 h, the cells were transfected with the pGloSensor™ cAMP
Plasmid using the Lipofectamine3000 transfection reagent as above. Between 24
and 48 h later, allowing for the accumulation of the biosensor, the medium in the
96-well plate was changed to CO2-independent medium supplemented with Glu-
taMAX™ (Life Technologies), 10% foetal bovine serum and 2% GloSensor™ cAMP
Reagent. The plate was then stored for 2 h at room temperature to equilibrate.
Following the incubation period, the cells were treated with relevant drugs and
their luminescence values were measured after 20 min in the BMG FLUOstar
OPTIMA Microplate Reader, with forskolin as a positive control, and DMSO as a
negative control.
Western blotting. 8–10 μg of SCN or U2OS total protein in RIPA buffer were run
on 4–20% SDS-PAGE gels (NuPAGE, Life Technologies), transferred using stan-
dard protocols (Bio-Rad) onto Immobilon FL PVDF membranes (Millipore),
blocked with Odyssey blocking buffer (Li-Cor Biosciences, Lincoln, NE, USA)
incubated with rabbit polyclonal antibodies to ERK1/2 (Rabbit anti- p44/42 MAPK
ERK1/2 137F5 #4695, Cell Signalling Technology used at 1:1000), pERK (Rabbit
anti- p44/42 MAPK ERK1/2 T202/204, #4370 Cell Signalling Technology, used at
1:2000), CREB (Rabbit anti- CREB 48H2 #9197 Cell Signalling Technology, used at
1:1000), pCREB (Rabbit anti- Phospho-CREB Ser133 87G3 #9198 Cell Signalling
Technology, used at 1:1000) and A-Tubulin (Mouse anti- A-Tubulin DM1A #3873,
Cell Signalling Technology, used at 1:5000), subsequently with donkey anti-rabbit
IgG LiC or 680 secondary antibody and scanned with the Odessey Li-Cor system.
Immunohistochemistry. Immunostaining procedures were performed on free-
floating sections. Briefly following euthanasia and dissection as outlined above, the
brains were postfixed in 4% v/v para formaldehyde and 10% w/v sucrose in 0.1 M
phosphate buffer saline at 4 °C overnight. The following day, brains were sliced into
50 µm sections using a compressotome and washed 3 times with 0.1% Tris-Triton
solution for 10 min under gentle agitation and blocked with 5% goat serum in 0.1%
Tris-Triton solution. Primary antibodies ADORA1 (AAR-006) and ADORA2a
(AAR-002, Alomone Labs) were used at 1:1000 and 1:500 dilutions and incubated
overnight under agitation at 4 °C. The next day following 3 washes of 15 min each
with 0.05% tween20-tris solution, the slices were incubated for 1 h at room tem-
perature with IRDYE 800 CW conjugated donkey anti-rabbit IgG (H+ L) (1:5000
dilution). The slices further underwent 3 washes of 15 min each with 0.05%
tween20-tris solution prior to being mounted in the presence of Prolong diamond
antifade mountant. The slices were imaged using Odyssey infrared imager at a
resolution of 21 μm, with 1 mm offset with highest quality.
Ca2+ imaging. Compounds were tested for their ability to release Ca2+ in U2OS
cells grown in Dulbecco’s modified Eagle medium containing 10% foetal bovine
serum at a range of concentrations as indicated (3–4 replicates). Ca2+ measure-
ments were performed on confluent cells growing in 96-well plates by incubating
with 2 μM fura-2-acetoxymethylester-LeakRes for 45 min in the presence of .1%
Pluronic F-127 at room temperature. Fluorescence measurements were performed
at λex= 340 nm, λex= 380 nm and λem= 526 nm in a Optima plate reader (BMG
LABTECH Ltd.). Following data acquisition the 340ex/526em fluorescence (in
arbitrary units) was divided 380ex/526em fluorescence and the data was expressed as
a ratio.
Adenosine measurement. C57/BL6, housed in 12:12 LD cycle were sacrificed using
cervical dislocation followed by decapitation at appropriate times. Brains were
extracted and coronal brain matrices were used to obtain 1 mm sections. The SCNs
or basal forebrain were punched out and rapidly transferred to a chamber con-
taining 50 μl oxygenated NMDG media and 200 nM adenosine kinase inhibitor
ABT 702 dihydrochloride (Tocris Bioscience). 5–7 punches were pooled per
sample. Following 30 min incubation, the samples were spun for 10 min at 3000
RCF and the supernatant extracted. The SCNs were stored in the freezer for further
protein quantification. The supernatant was filtered using a Sartorius-vivaspin
10,000 molecular weight cut-off filter to separate the media from secreted enzymes
and freeze-dried for storage in −20 °C.
The assay was performed using a coupled enzyme reaction adapted from ref. 10
such that adenosine in the brain samples or standard was converted to inosine >
hypoxanthine > xanthine+ hydrogen peroxide using the Adenosine Assay Kit
(Abcam – MET-5090). The mix was incubated for 30 min at RT in the dark in 100
mM phosphate buffer, pH 7.4. The resulting hydrogen peroxide was concurrently
detected in the presence of 0.05U/sample horseradish peroxidase (Abcam) and
Oxired probe at 1:25 dilution (Abcam) and the fluorescence was measured using a
Berthold plate reader with excitation 535 nm and emission 587 nm. In parallel, half
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the volume of the extracted samples was assayed as above, but with the omissision
of adenosine deaminase to account for background. The data was analysed by
subtracting the fluorescence values obtained from samples from their background
and normalising to protein content.
Quantification and statistical analysis. All statistical analyses were performed on
Graph Pad Prism 8.0 software, individual tests (all two-sided) and significance
levels, n (always biological replicates) as reported in each figure and corresponding
legend. Measurements were taken from distinct samples, other than phase-shifting
and re-entrainment protocols where each animal received four consecutive ran-
domised treatments.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The datasets generated during and/or analysed during the current study are listed below,
or available from the corresponding author on request. No codes were generated from
the currently study that are not already publicly available. Source data as below available
with this paper. RNA-seq data: https://usegalaxy.org/u/ajagannath/h/starprom2015.
Mass spectrometry data: Supplementary datasets. Original uncut blots: Supplementary
material. Source data for all figures are provided as a Source Data file. All other data such
as PCRs and actograms are available on request from corresponding author. Source data
are provided with this paper.
Code availability
STAR-PROM analysis code: https://github.com/randogp/STARprom
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